Bispecific IgG (BsIgG) Generation Services

Accelerate Your Research and Development!

Are you currently facing long drug development cycles, complex chain mispairing, and difficulty in achieving high-purity protein expression for your next-generation biologic? Our Bispecific IgG Generation Services help you accelerate drug discovery and develop highly specific antibodies through advanced structure-guided engineering techniques. We ensure your therapeutic candidates possess the highest levels of purity, stability, and function required for clinical success.

Contact our team to get an inquiry now!

Bispecific IgG Generation

Bispecific IgGs (BsIgGs) are advanced IgG-based therapeutic proteins capable of binding two distinct targets, making them critical in oncology, particularly as T-cell engagers. These molecules retain the native IgG structure and the Fc region, ensuring a long molecular half-life, and the ability to undergo Fc engineering (e.g., modulating ADCC or CDC). However, the primary manufacturing challenge, especially for IgG-like formats (monovalent for each antigen), is obtaining high-purity heterodimers. The co-expression of two heavy and two light chains often yield low amounts of the desired BsIgG alongside mispaired IgG contaminants. To resolve this developability challenge, advanced engineering strategies are applied to force correct chain association.

Fig.1 Examples of BsAb formats and structural diversity.^1,3

We categorize BsIgGs into two main architectural classes. IgG-like Formats (Class I) possess an asymmetric structure, highly similar to conventional IgG with 1+1 antigen valency. Their critical production challenge is managing required heterodimerization to avoid chain mismatch; which can be addressed using specialized technologies like Knobs-into-Holes (KiH), domain crossover, etc. In contrast, Appended IgG Formats (Class II) are built upon a conventional IgG backbone by fusing additional binding structures (e.g., Fab, scFv, VHH) via linkers. This design allows for flexible, often multivalent, binding (e.g., 1+2, 2+2) and largely bypasses HC/LC mispairing, although success depends on robust linker design and domain stability. Key examples include IgG-scFv and Fab-IgG.

Creative Biolabs uses advanced techniques to generate a wide variety of fully functional bispecific IgG antibodies. The bispecific IgG antibodies include:

IgG-like

Knobs-in-holes (KIH) BsIgG

CrossMab BsIgG

Fab-arm Exchange (FAE) BsAb

Charge pair BsAb

Fab-scFv-Fc BsAb

Appended IgG

IgG-scFv BsAb

IgG-Fv BsAb

IgG-Fab BsAb

Why Choose Us?

Creative Biolabs stands apart through our commitment to manufacturability and clinical viability, enforced by leading-edge proven engineering platforms. We don't just create BsAbs; we engineer them for success from the gene level up.

Key Competitive Advantages

• Quantitative Chain Pairing: Our use of rational, charge-based orthogonal Fab design, including CrossMab technology, ensures correct Heavy-Light Chain pairing, resulting in high yields (>90% purity often achieved) that drastically simplify downstream purification (often requiring only a single affinity step).
• Best-in-Class Heterodimerization: We leverage optimized Knobs-into-Holes (KiH) variants and Electrostatic Steering mutations in the C_H3 domain to guarantee efficient and stable HC:HC heterodimer formation.
• Advanced Analytical Rigor: Our use of Flow-Induced Dispersion Analysis (FIDA) validates dual binding in solution, bypassing the geometrical artifacts of traditional surface-based assays. This provides the most accurate functional assessment, confirmed by comprehensive Intact Mass Spectrometry and DSF data.
• Preclinical Acceleration: We specialize in the rapid design and expression of functional mouse surrogate BsAbs, essential for swift preclinical screening and T-cell engager development, accelerating your pipeline toward IND readiness.

Experience the Creative Biolabs Advantage - Get a Quote Today

Published Data

Fig.2 Bispecific IgG-based formats and overview of 2xVH IgG and Fab format.^2,3

The 2xVH bispecific format, structurally engineered to resemble a native immunoglobulin G (IgG), was introduced to confer bivalency against any target epitope while obviating the need for complex cognate chain pairing engineering. This architecture incorporates two distinct V_H domains, each recognizing a separate antigen, integrated directly into the C_H1 and C_L constant domains to generate dual binding specificity. Comprehensive analysis of the expression, binding affinity, and thermal stability of various human V_H modules facilitated the production of prototype 2xVH IgG and Fab constructs based on a standard IgG framework. Critically, the resulting molecules displayed biophysical characteristics comparable to conventional monoclonal antibodies (mAbs), thereby simplifying post-expression purification protocols while effectively retaining bivalent, dual-target affinity. Consequently, the 2xVH format resolves key manufacturing challenges associated with asymmetric IgG-like bispecifics and simultaneously enables biologically pertinent co-engagement of two distinct targets.

FAQs